MCID: DSR052
MIFTS: 28

Disorder of Glyoxylate Metabolism

Categories: Endocrine diseases, Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Disorder of Glyoxylate Metabolism

MalaCards integrated aliases for Disorder of Glyoxylate Metabolism:

Name: Disorder of Glyoxylate Metabolism 58
Hyperoxaluria 33

Classifications:

Orphanet: 58  
Inborn errors of metabolism


Summaries for Disorder of Glyoxylate Metabolism

MalaCards based summary: Disorder of Glyoxylate Metabolism, also known as hyperoxaluria, is related to hyperoxaluria, primary, type i and hyperoxaluria, primary, type ii. The drugs Dapagliflozin and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and bone marrow.

Related Diseases for Disorder of Glyoxylate Metabolism

Diseases related to Disorder of Glyoxylate Metabolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
# Related Disease Score Top Affiliating Genes
1 hyperoxaluria, primary, type i 11.8
2 hyperoxaluria, primary, type ii 11.8
3 hyperoxaluria, primary, type iii 11.4
4 nephrolithiasis, calcium oxalate 11.3
5 primary hyperoxaluria 11.2
6 crystal arthropathies 10.9
7 nephrocalcinosis 10.9
8 nephrolithiasis 10.9
9 end stage renal disease 10.9
10 urolithiasis 10.8
11 kidney disease 10.6
12 chronic kidney disease 10.6
13 abdominal obesity-metabolic syndrome 1 10.4
14 urinary tract infection 10.4
15 acute kidney failure 10.3
16 inherited metabolic disorder 10.3
17 bone disease 10.2
18 hypoascorbemia 10.2
19 hyperparathyroidism 10.2
20 leptin deficiency or dysfunction 10.2
21 metabolic acidosis 10.2
22 leptin receptor deficiency 10.2
23 renal tubular acidosis 10.2
24 renal osteodystrophy 10.1
25 intestinal disease 10.1
26 gastrointestinal system disease 10.1
27 crohn's disease 10.1
28 uremia 10.1
29 distal renal tubular acidosis 10.1
30 idiopathic hypercalciuria 10.1
31 pancreatitis, hereditary 10.1
32 bietti crystalline corneoretinal dystrophy 10.1
33 celiac disease 1 10.1
34 aplastic anemia 10.1
35 inflammatory bowel disease 10.1
36 short bowel syndrome 10.1
37 rickets 10.1
38 pancytopenia 10.1
39 secondary hyperparathyroidism 10.1
40 acute kidney tubular necrosis 10.1
41 liver disease 10.1
42 urinary tract obstruction 10.1
43 neuropathy 10.1
44 peroxisomal disease 10.1
45 bowel dysfunction 10.1
46 down syndrome 10.0
47 inflammatory bowel disease 1 10.0
48 urinary tract infections, recurrent 10.0
49 pyelonephritis 10.0
50 diarrhea 10.0

Graphical network of the top 20 diseases related to Disorder of Glyoxylate Metabolism:



Diseases related to Disorder of Glyoxylate Metabolism

Symptoms & Phenotypes for Disorder of Glyoxylate Metabolism

Drugs & Therapeutics for Disorder of Glyoxylate Metabolism

Drugs for Disorder of Glyoxylate Metabolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapagliflozin Approved Phase 4 461432-26-8 9887712
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3 Antihypertensive Agents Phase 4
4 Sodium-Glucose Transporter 2 Inhibitors Phase 4
5 Hypoglycemic Agents Phase 4
6 Sodium Chloride Symporter Inhibitors Phase 4
7 diuretics Phase 4
8
Lumasiran Approved, Investigational Phase 3 1834610-13-7
9 Pharmaceutical Solutions Phase 3
10
Stiripentol Approved Phase 2 49763-96-4 5311454
11
N,N,N-trimethylglycinium Approved, Experimental, Investigational, Nutraceutical Phase 2 6915-17-9, 107-43-7 248
12
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
13
Pyridoxal phosphate Approved, Investigational, Nutraceutical Phase 2 54-47-7 1051
14 Anticonvulsants Phase 2
15 Antimetabolites Phase 2
16 Hypolipidemic Agents Phase 2
17 Lipid Regulating Agents Phase 2
18 Gastrointestinal Agents Phase 2
19 Vitamin B6 Phase 2
20 Vitamin B 6 Phase 2
21 Brewer's Yeast Phase 1, Phase 2
22 Acidophilus Phase 1, Phase 2
23
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
24
D-Leucine Experimental, Investigational, Nutraceutical Phase 1, Phase 2 328-38-1, 61-90-5 439524 6106
25
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
26
Tannic acid Approved Phase 1 1401-55-4 16129878 16129778
27 Liver Extracts Phase 1
28
Bilberry Approved, Experimental
29
Turmeric Approved, Experimental, Investigational
30 Cinnamon Approved
31 Cranberry Approved, Investigational
32
Milk thistle Approved, Experimental, Investigational 65666-07-1
33
Ascorbic acid Approved, Nutraceutical 50-81-7 54676860 54670067 5785
34 Aloe
35 Turmeric extract
36 Tea

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Dapagliflozin and Hydrochlorothiazide Treatment in Recurring Kidney Stone Patients - a Randomised Single Center Cross-over Study Not yet recruiting NCT05443932 Phase 4 Dapagliflozin;Hydrochlorothiazide
2 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria Completed NCT00638703 Phase 2, Phase 3 Placebo
3 A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria. Completed NCT01037231 Phase 2, Phase 3 Placebo
4 A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria Completed NCT03116685 Phase 3
5 Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study Completed NCT03456830 Phase 3 ALLN-177;Placebo
6 Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis: a Short-term, Prospective, Open-label, Efficacy and Safety Clinical Trial Recruiting NCT03346369 Phase 3 Lanthanum Carbonate
7 ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1) Active, not recruiting NCT04152200 Phase 3 Lumasiran
8 ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 Active, not recruiting NCT03905694 Phase 3 Lumasiran
9 ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 Active, not recruiting NCT03681184 Phase 3 Placebo;Lumasiran
10 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
11 Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2) Terminated NCT03847090 Phase 3 Reloxaliase;Placebo
12 An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02 Terminated NCT03938272 Phase 3
13 Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria Withdrawn NCT00280215 Phase 3 ACEI / Angiotensin converting enzyme inhibitor;ARB /Angiotensin Receptor Blocker;Placebo
14 A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones Completed NCT02547805 Phase 2 ALLN-177;Placebo
15 A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Completed NCT02503345 Phase 2 ALLN-177 low dose;ALLN-177 mid dose;ALLN-177 high dose;Placebo
16 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Completed NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
17 Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia Completed NCT03391804 Phase 2 ALLN-177
18 A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Completed NCT02289755 Phase 2 ALLN-177
19 A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1 Completed NCT02706886 Phase 1, Phase 2 Lumasiran;Placebo
20 A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis Completed NCT02000219 Phase 2
21 Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria Completed NCT03819647 Phase 2 stiripentol (Diacomit)
22 A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria Completed NCT02012985 Phase 1, Phase 2 Placebo capsules
23 A Pilot Study to Evaluate the Safety and Efficacy of Oxazyme (OC4) in Patients With Hyperoxaluria Completed NCT01127087 Phase 1, Phase 2 Oxazyme
24 Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria Completed NCT00283387 Phase 2 Betaine;Placebo
25 PILOTSTUDIE ZUR PYRIDOXALPHOSPHATTHERAPIE BEI PATIENTEN MIT PRIMÄRER HYPEROXALURIE TYP I (PHOX-B6-PILOT) Pilot Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate Completed NCT01281878 Phase 2 Vitamin B 6
26 Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate Completed NCT02038543 Phase 1, Phase 2 Hydroxyproline and Leucine
27 Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Completed NCT00587041 Phase 1, Phase 2
28 A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function Recruiting NCT05001269 Phase 2 nedosiran
29 A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis Recruiting NCT04580420 Phase 2 DCR-PHXC
30 Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria Recruiting NCT04909723 Phase 1, Phase 2 NB2000P;Placebo
31 A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1 Active, not recruiting NCT03350451 Phase 2 Lumasiran
32 Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria Withdrawn NCT00490113 Phase 2 Pyridoxamine
33 Investigations Into the Genotype and Phenotype of Unclassified Hyperoxaluria: Enteric Oxalate Absorption Study Completed NCT00588120 Phase 1 C-13 labeled oxalate
34 A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3 Completed NCT04555486 Phase 1 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
35 A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use) Completed NCT03392896 Phase 1 DCR-PHXC;Placebo
36 A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients With Enteric Hyperoxaluria Recruiting NCT04629170 Phase 1 SYNB8802;Placebo
37 A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) Terminated NCT02795325 Phase 1 DCR-PH1
38 Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients Unknown status NCT02794649
39 Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1 Approved for marketing NCT04125472 Lumasiran
40 A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria Completed NCT03095885
41 "Pilot Study: Proteomics of Primary Hyperoxaluria Type 1 (PH1): A Rare Calcium Oxalate Stone Disease" Completed NCT03067142
42 Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria Completed NCT00589225
43 Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria Completed NCT02340689
44 IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA Completed NCT02830009
45 Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium Completed NCT02124395
46 Determination of Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children of Pakistani Origin Under Six Years of Age Completed NCT04756024
47 Plasma Oxalate in Patient With Short Bowel Completed NCT04119765
48 Relationship of Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate Excretion in Patients With Urolithiasis Completed NCT04571359
49 Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk Completed NCT02404701
50 Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers Completed NCT00199459

Search NIH Clinical Center for Disorder of Glyoxylate Metabolism

Genetic Tests for Disorder of Glyoxylate Metabolism

Anatomical Context for Disorder of Glyoxylate Metabolism

Organs/tissues related to Disorder of Glyoxylate Metabolism:

MalaCards : Kidney, Liver, Bone Marrow, Small Intestine, Bone, Spinal Cord, Colon

Publications for Disorder of Glyoxylate Metabolism

Articles related to Disorder of Glyoxylate Metabolism:

(show top 50) (show all 2715)
# Title Authors PMID Year
1
Preemptive liver transplant in two patients with primary hyperoxaluria type 1: Clinical significance of nephrolithiasis and nephrocalcinosis. 62
35979862 2022
2
Metabolic and Genetic Evaluation in Children with Nephrolithiasis. 62
35819704 2022
3
A pilot dynamic analysis of formative factors of nephrolithiasis related to metabolic syndrome: evidence in a rat model. 62
35837686 2022
4
Cutaneous Oxalosis Due to Primary Hyperoxaluria. 62
36395453 2022
5
Increased Rates of Supplement-Associated Oxalate Nephropathy During COVID-19 Pandemic. 62
36120391 2022
6
Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. 62
36472654 2022
7
Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias. 62
36113265 2022
8
Chitosan derivatives as nanocarriers for hLDHA inhibitors delivery to hepatic cells: A selective strategy for targeting primary hyperoxaluria diseases. 62
36181922 2022
9
Secondary oxalate nephropathy and kidney transplantation. 62
36342385 2022
10
Clinical exome sequencing uncovers an unsuspected diagnosis of Bartter syndrome type 2 in a child with incidentally detected nephrocalcinosis. 62
35195872 2022
11
Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1. 62
36449101 2022
12
Searching glycolate oxidase inhibitors based on QSAR, molecular docking, and molecular dynamic simulation approaches. 62
36402831 2022
13
Dominant negative mutation in oxalate transporter SLC26A6 associated with enteric hyperoxaluria and nephrolithiasis. 62
35115415 2022
14
Etiology, urine metabolic risk factors, and urine oxalate patterns in patients with significant hyperoxaluria and recurrent nephrolithiasis. 62
35917078 2022
15
Pediatric urolithiasis: what can pediatricians expect from radiologists? 62
36329164 2022
16
Oxalate homeostasis. 62
36329260 2022
17
Clinical and molecular characterization of a large primary hyperoxaluria cohort from Saudi Arabia: a retrospective study. 62
36409364 2022
18
CRISPR/Cas9-mediated knock-out of AGXT1 in HepG2 cells as a new in vitro model of Primary Hyperoxaluria Type 1. 62
35964771 2022
19
Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies. 62
36407951 2022
20
What treatments reduce kidney stone risk in patients with bowel disease? 62
35976425 2022
21
Analysis and Characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei: Two Probiotic Bacteria that Can Degrade Intestinal Oxalate in Hyperoxaluric Rats. 62
35699895 2022
22
Diagnostic Code-Based Screening for Identifying Children with Primary Hyperoxaluria. 62
35930731 2022
23
Retraction: Molecular Diagnosis of Primary Hyperoxaluria Type 1 and Distal Renal Tubular Acidosis in Moroccan Patients With Nephrolithiasis and/or Nephrocalcinosis. 62
36246090 2022
24
Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of 5 cases. 62
36307929 2022
25
The retinal phenotype in primary hyperoxaluria type 2 and 3. 62
36260161 2022
26
Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review. 62
36250252 2022
27
Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I. 62
36202824 2022
28
A case report of invasive infantile primary hyperoxaluria type 1 and literature review. 62
36194362 2022
29
HOGA1 gene pathogenic variants in primary hyperoxaluria type III: Spectrum of pathogenic sequence variants, and phenotypic association. 62
36259736 2022
30
Primary hyperoxaluria: Comprehensive mutation screening of the disease causing genes and spectrum of disease-associated pathogenic variants. 62
36185032 2022
31
Clinical and molecular characterization of primary hyperoxaluria in Egypt. 62
36151119 2022
32
Primary Hyperoxaluria: A Need for New Perspectives in an Era of New Therapies. 62
36184293 2022
33
4-PBA rescues hyperoxaluria induced nephrolithiasis by modulating urinary glycoproteins: Cross talk between endoplasmic reticulum, calcium homeostasis and mitochondria. 62
35809664 2022
34
A Friend or a Foe? Bariatric Surgery in Chronic Kidney Disease: A Case Report. 62
36465578 2022
35
Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. 62
35306035 2022
36
Therapeutic siRNA: State-of-the-Art and Future Perspectives. 62
35997897 2022
37
Postbiotics and Kidney Disease. 62
36136562 2022
38
Probiotic Oxalate-Degrading Bacteria: New Insight of Environmental Variables and Expression of the oxc and frc Genes on Oxalate Degradation Activity. 62
36141002 2022
39
Nephro-protective effect of Daphnetin in hyperoxaluria-induced rat renal injury via alterations of the gut microbiota. 62
35994414 2022
40
Whole-exome sequencing and variant spectrum in children with suspected inherited renal tubular disorder: the East India Tubulopathy Gene Study. 62
35006361 2022
41
Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. 62
35913563 2022
42
Primary hyperoxaluria and genetic linkages: an insight into the disease burden from Pakistan. 62
35678848 2022
43
Next-generation sequencing in identification of pathogenic variants in primary hyperoxaluria among 21 Egyptian families: Identification of two novel AGXT gene mutations. 62
35661454 2022
44
Lessons for the clinical nephrologist: lumasiran as the future cornerstone treatment for patients with primary hyperoxaluria type 1? 62
35986861 2022
45
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. 62
36007597 2022
46
The appearance of oxalate crystals in a kidney biopsy is no proof of post-transplant oxalate nephropathy in primary hyperoxaluria type 1. 62
35870818 2022
47
Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry. 62
35812297 2022
48
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. 62
35843439 2022
49
Progress with RNA Interference for the Treatment of Primary Hyperoxaluria. 62
35731461 2022
50
Primary hyperoxaluria type 1: report of the worldwide largest family. 62
34796413 2022

Variations for Disorder of Glyoxylate Metabolism

Expression for Disorder of Glyoxylate Metabolism

Search GEO for disease gene expression data for Disorder of Glyoxylate Metabolism.

Pathways for Disorder of Glyoxylate Metabolism

GO Terms for Disorder of Glyoxylate Metabolism

Sources for Disorder of Glyoxylate Metabolism

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....